Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use

Osteoarthritis and Cartilage

Volumn 23, Issue 8, 2015, Pages 1233-1241

  Kraus, V B ^a   Blanco, F J ^b   Englund, M ^c,d   Karsdal, M A ^e   Lohmander, L S ^c,f  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c LUND UNIVERSITY   (Sweden)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORDIC BIOSCIENCE A S   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Anatomy; Biomarkers; Criteria; Definition; Osteoarthritis; Physiology

Indexed keywords

CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DISEASE ACTIVITY SCORE; DISEASE CLASSIFICATION; FRAX; HEALTH STATUS; HIP OSTEOARTHRITIS; HUMAN; JOINT RADIOGRAPHY; KNEE OSTEOARTHRITIS; MOLECULAR DIAGNOSIS; NOMENCLATURE; OSTEOARTHRITIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RELIABLE EARLY DISEASE IDENTIFICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK OF OSTEOARTHRITIS DEVELOPMENT; RISK OF OSTEOARTHRITIS PROGRESSION; SENSITIVITY AND SPECIFICITY; STANDARD; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HEALTH PROMOTION; OSTEOPOROTIC FRACTURES; OUTCOME ASSESSMENT; STANDARDS;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HEALTH PROMOTION; HUMANS; OSTEOARTHRITIS; OSTEOPOROTIC FRACTURES; PATIENT OUTCOME ASSESSMENT; RISK ASSESSMENT; TERMINOLOGY AS TOPIC;

EID: 84938216409     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2015.03.036     Document Type: Review

References (80)

1. Simoncell T., Barclay L., Bouri K., Burns K., Cook K., Filice R., et al. Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development 2013, 1-61. In, vol. October. Silver Spring, MD.
2. Desmond-Hellmann S., Sawyers C., Cox D., Fraser-Liggett C., Galli S., Goldstein D., et al. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 2011, National Academy of Sciences, Washington DC.
3. Nordqvist C. What is Physiology. Medical News Today 2014, Medical News Today.
4. Castaneda S., Roman-Blas J.A., Largo R., Herrero-Beaumont G. Osteoarthritis: a progressive disease with changing phenotypes. Rheumatology (Oxford) 2014, 53:1-3.
5. Helman C.G. Disease versus illness in general practice. J R Coll Gen Pract 1981, 31:548-552.
6. Rudwaleit M., van der Heijde D., Landewe R., Listing J., Akkoc N., Brandt J., et al. The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
7. Anonymous Treatment Trials for Nonradiologic axSpA (nr-axSpA) Followed the Development of Diagnostic Criteria by ASAS in 2009. Rheumatology News 2014.
8. Cibere J., Zhang H., Garnero P., Poole A.R., Lobanok T., Saxne T., et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 2009, 60:1372-1380.
9. De Vecchis R., Esposito C., Di Biase G., Ariano C., Giasi A., Cioppa C. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis. J Cardiovasc Med (Hagerstown) 2014, 15:122-134.
10. Savarese G., Trimarco B., Dellegrottaglie S., Prastaro M., Gambardella F., Rengo G., et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One 2013, 8:e58287.
11. Vasara A.I., Jurvelin J.S., Peterson L., Kiviranta I. Arthroscopic cartilage indentation and cartilage lesions of anterior cruciate ligament-deficient knees. Am J Sports Med 2005, 33:408-414.
12. Kraus V.B., Burnett B., Coindreau J., Cottrell S., Eyre D., Gendreau M., et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011, 19:515-542.
13. Ling S.M., Patel D.D., Garnero P., Zhan M., Vaduganathan M., Muller D., et al. Serum protein signatures detect early radiographic osteoarthritis. Osteoarthritis Cartilage 2009, 17:43-48.
14. Golightly Y., Marshall1 S., Kraus V., Renner J., Villaveces A., Casteel1 C., et al. Serum cartilage oligomeric matrix protein, hyalutonan, high-sensitivity C-reactive protein and keratan sulfate as predictors of incident radiographic knee osteoarthritis: differences by chronic knee symptoms. Osteoarthritis Cartilage 2010, 18:S62-S63.
15. Ruiz-Romero C., Blanco F.J. Proteomics role in the search for improved diagnosis, prognosis and treatment of osteoarthritis. Osteoarthritis Cartilage 2010, 18:500-509.
16. Chen C., Tambe D.T., Deng L., Yang L. Biomechanical properties and mechanobiology of the articular chondrocyte. Am J Physiol Cell Physiol 2013, 305:C1202-C1208.
17. Catterall J.B., Hsueh M.F., Stabler T.V., McCudden C.R., Bolognesi M., Zura R., et al. Protein modification by deamidation indicates variations in joint extracellular matrix turnover. J Biol Chem 2012, 287:4640-4651.
18. Catterall J., Zura R., Bolognesi M., Kraus V. Amino acid racemization reveals a high state of repair in knee compared with hip. Osteoarthritis Cartilage 2013, 21(Suppl):S108.
19. Stabler T.V., Byers S.S., Zura R.D., Kraus V.B. Amino acid racemization reveals differential protein turnover in osteoarthritic articular and meniscal cartilages. Arthritis Res Ther 2009, 11:R34.
20. Blanco F.J., Ruiz-Romero C. New targets for disease modifying osteoarthritis drugs: chondrogenesis and Runx1. Ann Rheum Dis 2013, 72:631-634.
21. Koelling S., Kruegel J., Irmer M., Path J.R., Sadowski B., Miro X., et al. Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. Cell Stem Cell 2009, 4:324-335.
22. O'Conor C.J., Leddy H.A., Benefield H.C., Liedtke W.B., Guilak F. TRPV4-mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading. Proc Natl Acad Sci U S A 2014, 111:1316-1321.
23. Vincent T.L. Targeting mechanotransduction pathways in osteoarthritis: a focus on the pericellular matrix. Curr Opin Pharmacol 2013, 13:449-454.
24. Milner P., Wilkins R., Gibson J. Cellular physiology of articular cartilage in health and disease. Principles of Osteoarthritis - its Definition, Character, Derivation and Modality-related Recognition 2012, InTech. B. Rothschild (Ed.).
25. Hsueh M.F., Onnerfjord P., Kraus V.B. Biomarkers and proteomic analysis of osteoarthritis. Matrix Biol 2014, 39C:56-66.
26. Mateos J., Lourido L., Fernandez-Puente P., Calamia V., Fernandez-Lopez C., Oreiro N., et al. Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF. J Proteomics 2012, 75:2869-2878.
27. Ritter S.Y., Subbaiah R., Bebek G., Crish J., Scanzello C.R., Krastins B., et al. Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis Rheum 2013, 65:981-992.
28. Fernandez-Puente P., Mateos J., Fernandez-Costa C., Oreiro N., Fernandez-Lopez C., Ruiz-Romero C., et al. Identification of a panel of novel serum osteoarthritis biomarkers. J Proteome Res 2011, 10:5095-5101.
29. Rigoglou S., Papavassiliou A.G. The NF-kappaB signalling pathway in osteoarthritis. Int J Biochem Cell Biol 2013, 45:2580-2584.
30. Kraus V.B. Osteoarthritis: the zinc link. Nature 2014, 507:441-442.
31. Scanzello C.R., Plaas A., Crow M.K. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. Curr Opin Rheumatol 2008, 20:565-572.
32. Takayama K., Kawakami Y., Lee S., Greco N., Lavasani M., Mifune Y., et al. Involvement of ERCC1 in the pathogenesis of osteoarthritis through the modulation of apoptosis and cellular senescence. J Orthop Res 2014, 32:1326-1332.
33. Mobasheri A., Matta C., Zakany R., Musumeci G. Chondrosenescence: definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas 2015, 80:237-244.
34. Heard B.J., Martin L., Rattner J.B., Frank C.B., Hart D.A., Krawetz R. Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid. BMC Musculoskelet Disord 2012, 13:126.
35. Onnerfjord P., Khabut A., Reinholt F.P., Svensson O., Heinegard D. Quantitative proteomic analysis of eight cartilaginous tissues reveals characteristic differences as well as similarities between subgroups. J Biol Chem 2012, 287:18913-18924.
36. Pritzker K.P., Gay S., Jimenez S.A., Ostergaard K., Pelletier J.P., Revell P.A., et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006, 14:13-29.
37. Roemer F.W., Guermazi A., Felson D.T., Niu J., Nevitt M.C., Crema M.D., et al. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann Rheum Dis 2011, 70:1804-1809.
38. Guermazi A., Niu J., Hayashi D., Roemer F.W., Englund M., Neogi T., et al. Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: population based observational study (Framingham Osteoarthritis Study). BMJ 2012, 345:e5339.
39. Choi J.A., Gold G.E. MR imaging of articular cartilage physiology. Magn Reson Imaging Clin N Am 2011, 19:249-282.
40. Hunter D., Lohmander L., Makovey J., Tamez-Pena J., Totterman S., Schreyer E., et al. The effect of anterior cruciate ligament injury on bone curvature: the KANON Trial. Osteoarthritis Cartilage 2014, 22:959-968.
41. Reichenbach S., Guermazi A., Niu J., Neogi T., Hunter D.J., Roemer F.W., et al. Prevalence of bone attrition on knee radiographs and MRI in a community-based cohort. Osteoarthritis Cartilage 2008, 16:1005-1010.
42. Hunter D.J., Arden N., Conaghan P.G., Eckstein F., Gold G., Grainger A., et al. Definition of osteoarthritis on MRI: results of a Delphi exercise. Osteoarthritis Cartilage 2011, 19:963-969.
43. Moller I., Bong D., Naredo E., Filippucci E., Carrasco I., Moragues C., et al. Ultrasound in the study and monitoring of osteoarthritis. Osteoarthritis Cartilage 2008, 16(Suppl 3):S4-S7.
44. Keen H.I., Wakefield R.J., Grainger A.J., Hensor E.M., Emery P., Conaghan P.G. Can ultrasonography improve on radiographic assessment in osteoarthritis of the hands? A comparison between radiographic and ultrasonographic detected pathology. Ann Rheum Dis 2008, 67:1116-1120.
45. Ashraf S., Walsh D.A. Angiogenesis in osteoarthritis. Curr Opin Rheumatol 2008, 20:573-580.
46. Kloppenburg M., Kwok W.Y. Hand osteoarthritis - a heterogeneous disorder. Nat Rev Rheumatol 2012, 8:22-31.
47. Haugen I.K., Lillegraven S., Slatkowsky-Christensen B., Haavardsholm E.A., Sesseng S., Kvien T.K., et al. Hand osteoarthritis and MRI: development and first validation step of the proposed Oslo Hand Osteoarthritis MRI score. Ann Rheum Dis 2011, 70:1033-1038.
48. McDonough C.M., Jette A.M. The contribution of osteoarthritis to functional limitations and disability. Clin Geriatr Med 2010, 26:387-399.
49. Block J.A., Shakoor N. The biomechanics of osteoarthritis: implications for therapy. Curr Rheumatol Rep 2009, 11:15-22.
50. Roos E.M., Juhl C.B. Osteoarthritis 2012 year in review: rehabilitation and outcomes. Osteoarthritis Cartilage 2012, 20:1477-1483.
51. Kiviranta P., Lammentausta E., Toyras J., Kiviranta I., Jurvelin J.S. Indentation diagnostics of cartilage degeneration. Osteoarthritis Cartilage 2008, 16:796-804.
52. Shapiro L.M., Gold G.E. MRI of weight bearing and movement. Osteoarthritis Cartilage 2012, 20:69-78.
53. Sutter E.G., Widmyer M.R., Utturkar G.M., Spritzer C.E., Garrett W.E., DeFrate L.E. In vivo measurement of localized tibiofemoral cartilage strains in response to dynamic activity. Am J Sports Med 2015, 43:370-376.
54. Ornetti P., Maillefert J.F., Laroche D., Morisset C., Dougados M., Gossec L. Gait analysis as a quantifiable outcome measure in hip or knee osteoarthritis: a systematic review. Jt Bone Spine 2010, 77:421-425.
55. Kraus V. Preclinical osteoarthritis. Rheumatology 2014, 1498-1547. Mosby Elsevier, Philadelphia. M. Hochberg, A. Silman, J. Smolen, M. Weinblatt, M. Weisman (Eds.).
56. Zhang W., Doherty M., Peat G., Bierma-Zeinstra M.A., Arden N.K., Bresnihan B., et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 2010, 69:483-489.
57. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
58. Vaidya V.S., Ozer J.S., Dieterle F., Collings F.B., Ramirez V., Troth S., et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010, 28:478-485.
59. Bonventre J.V., Vaidya V.S., Schmouder R., Feig P., Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010, 28:436-440.
60. Henriksen K., Bohren K.M., Bay-Jensen A.C., Karsdal M.A. Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?. Biomarkers 2010, 15:195-204.
61. Levey A.S., Inker L.A., Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis 2014, 63:820-834.
62. Genovese F., Manresa A.A., Leeming D.J., Karsdal M.A., Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?. Fibrogenesis Tissue Repair 2014, 7:4.
63. Karsdal M.A., Krarup H., Sand J.M., Christensen P.B., Gerstoft J., Leeming D.J., et al. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 2014, 40:233-249.
64. Michalopoulos G.K. Advances in liver regeneration. Expert Rev Gastroenterol Hepatol 2014, 1-11.
65. Shoup M., Gonen M., D'Angelica M., Jarnagin W.R., DeMatteo R.P., Schwartz L.H., et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003, 7:325-330.
66. Schindl M.J., Redhead D.N., Fearon K.C., Garden O.J., Wigmore S.J. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut 2005, 54:289-296.
67. Vauthey J.N., Chaoui A., Do K.A., Bilimoria M.M., Fenstermacher M.J., Charnsangavej C., et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000, 127:512-519.
68. Lawrence J.S., Bremner J.M., Bier F. Osteo-arthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis 1966, 25:1-24.
69. Dieppe P.A., Lohmander L.S. Pathogenesis and management of pain in osteoarthritis. Lancet 2005, 365:965-973.
70. Arendt-Nielsen L., Nie H., Laursen M.B., Laursen B.S., Madeleine P., Simonsen O.H., et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010, 149:573-581.
71. Wluka A.E., Wolfe R., Stuckey S., Cicuttini F.M. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis?. Ann Rheum Dis 2004, 63:264-268.
72. Kim D.H., Schwartz C.E. The genetics of pain: implications for evaluation and treatment of spinal disease. Spine J 2010, 10:827-840.
73. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29:1039-1049.
74. Kanis J.A., Oden A., McCloskey E.V., Johansson H., Wahl D.A., Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012, 23:2239-2256.
75. Fardellone P. Predicting the fracture risk in 2008. Jt Bone Spine 2008, 75:661-664.
76. Kerkhof H.J., Bierma-Zeinstra S.M., Arden N.K., Metrustry S., Castano-Betancourt M., Hart D.J., et al. Prediction model for knee osteoarthritis incidence, including clinical, genetic and biochemical risk factors. Ann Rheum Dis 2014, 73:2116-2121.
77. Smolen J.S., Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 2013, 72:3-6.
78. Misko T.P., Radabaugh M.R., Highkin M., Abrams M., Friese O., Gallavan R., et al. Characterization of nitrotyrosine as a biomarker for arthritis and joint injury. Osteoarthritis Cartilage 2013, 21:151-156.
79. Katz D., Ather A. Preventive medicine, integrative medicine & the health of the public. Commissioned for the IOM Summit on Integrative Medicine and the Health of the Public 2009, 1-45. Institute of Medicine.
80. El-Zayadi A.R. Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol 2008, 14:4120-4126.